Business Context and Reporting Period
Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.) filed a Form 8-K Current Report on April 12, 2012. The filing announces the entry into a material definitive agreement for an underwritten public offering of common stock.
Key Financial Metrics
This filing details a capital raise rather than operational performance metrics. Key figures include:
- Shares Offered: 6,000,000 shares of common stock.
- Public Offering Price: $9.75 per share.
- Underwriting Price: $9.165 per share.
- Expected Net Proceeds: Approximately $54.6 million (after underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to an additional 900,000 shares at the same price.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report, not a periodic financial statement.
Material Changes
The primary material change is the execution of an underwriting agreement to raise capital. The offering is expected to close on April 17, 2012, subject to customary closing conditions. The shares are being issued pursuant to a shelf registration statement that became effective on April 5, 2012.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on operations, or a discussion of risks beyond the standard closing conditions for the offering. The transaction is contingent on the satisfaction of customary closing conditions.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected April 17, 2012) and confirm if the over-allotment option was exercised.
- Review the final prospectus supplement for the exact net proceeds received after all expenses.
- Check subsequent filings (e.g., 10-Q or 10-K) to determine how the $54.6 million in proceeds were utilized.
- Confirm the total share count post-offering to assess dilution impact.